Recombinant Human Interleukin-6 Induces Hepatocyte Growth Factor Production in Cancer Patients

References

• Taub R. Liver regeneration 4: transcriptional control of liver regeneration. FASEB J 1996;10:413–27.
   PubMed Web of Science ®Google Scholar
• Fausto N, Laird AD, Webber EM. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995;9: 1527–36.
   Google Scholar
• Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60–6.
   PubMed Web of Science ®Google Scholar
• Boros P, Miller CM. Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995;345:293–5.
   PubMed Web of Science ®Google Scholar
• Jiang WG, Hallett MB, Puntis MC. Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastasis. Br J Surg 1993;80:1368–73.
   Google Scholar
• Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84: 7251–5.
   Google Scholar
• Ramadori G, Van Damme J, Rieder H, Meyer zum Buschenfelde KH. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 1988;18: 1259–64.
   Google Scholar
• Billiar TR, Curran RD, Williams DL, Kispert PH. Liver nonparenchymal cells are stimulated to provide interleukin 6 for induction of the hepatic acute-phase response in endotoxemia but not in remote localized inflammation. Arch Surg 1992;127:31–6.
   PubMed Web of Science ®Google Scholar
• Ayala A, Perrin MM, Wang P, Chaudry IH. Sepsis induces an early increased spontaneous release of hepatocellular stimulatory factor (interleukin-6) by Kupffer cells in both endotoxin tolerant and intolerant mice. J Surg Res 1992;52:635–41.
   PubMedGoogle Scholar
• Brach MA Herrmann F. Interleukin 6: presence and future. Int J Clin Lab Res 1992;22:143–51.
   PubMedGoogle Scholar
• Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-defi cient mice. Science 1996;274: 1379–83.
   PubMed Web of Science ®Google Scholar
• Ohira H, Miyata M, Kuroda M, Takagi T, Tojo J, Ochiai H, et al. Interleukin-6 induces proliferation of rat hepatocytes in vivo. J Hepatol 1996;25:941–7.
   PubMedGoogle Scholar
• van Gameren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994;84:1434–41.
   PubMed Web of Science ®Google Scholar
• Hazenberg BPC, Limburg PC, Bijzet J, van Rijswijk MH. Monoclonal antibody based ELISA for human SAA. In: Natvig JB, Forre O, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P, editors. Amyloid and amyloidosis. Dordrecht: Kluwer Academic Press; 1991. p. 898–901.
   Google Scholar
• Helle M, Boeye L, de Groot E, de Vos A, Aarden LA. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991;138: 47–56.
   Google Scholar
• Tsubouchi H, Niitani Y, Hirono S, Nakayama H, Gohda E, Arakaki N, et al. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology 1991;13:1–5.
   PubMed Web of Science ®Google Scholar
• Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T. Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology 1995;21:106–12.
   Google Scholar
• Taniguchi T, Kitamura M, Arai K, Iwasaki Y, Yamamoto Y, Igari A, et al. Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer 1997; 75:673–7.
   PubMed Web of Science ®Google Scholar
• Gohji K, Nomi M, Niitani Y, Kitazawa S, Fujii A, Katsuoka Y, et al. Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol 2000;18:2963–71.
   PubMedGoogle Scholar
• de Jong KP, Alting von Geusau B, Rottier CA, Bijzet J, Limburg PC, de Vries EGE, et al. Serum response of hepatocyte growth factor, insulin-like growth factor-I, interleukin-6, and acute phase proteins in patients with colorectal liver metastases treated by partial hepatectomy or cryosurgery. J Hepatol 2001;34:422–7.
   PubMedGoogle Scholar
• Ho RT, Liew CT, Lai KN. The expression of hepatocyte growth factor (HGF) and interleukin 6 (IL-6) in damaged human liver and kidney tissues. Hepatogastroenterology 1999;46: 1904–9.
   Google Scholar
• Guillen MI, Gomez Lechon MJ, Nakamura T, Castell JV. The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on interleukin-6-stimulated genes. Hepatology 1996;23:1345–52.
   PubMedGoogle Scholar
• Wolf HK, Zarnegar R, Michalopoulos GK. Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study. Hepatology 1991;14:488–94.
   Google Scholar
• Bhargava M, Joseph A, Knesel J, Halaban R, Li Y, Pang S, et al. Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ 1992;3:11–20.
   PubMedGoogle Scholar
• Hart IR Saini A. Biology of tumour metastasis. Lancet 1992;339:1453–7.
   Google Scholar
• Maggiora P, Gambarotta G, Olivero M, Giordano S, Di Renzo MF, Comoglio PM. Control of invasive growth by the HGF receptor family. J Cell Physiol 1997;173:183–6.
   PubMedGoogle Scholar
• van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998;97:381–90.
   PubMed Web of Science ®Google Scholar
• Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickol-off BJ, Kinsella JL, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1937–41.
   PubMed Web of Science ®Google Scholar
• Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, et al. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 1998;4:659–64.
   PubMed Web of Science ®Google Scholar
• Maemura M, Iino Y, Yokoe T, Horiguchi J, Takei H, Koibuchi Y, et al. Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. Cancer Lett 1998;126: 215–20.
   PubMed Web of Science ®Google Scholar
• Yi S, Chen JR, Viallet J, Schwall RH, Nakamura T, Tsao MS. Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines. Br J Cancer 1998; 77:2162–70.
   PubMedGoogle Scholar
• Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett 1991;291:229–32.
   Google Scholar
• Shiota G, Rhoads DB, Wang TC, Nakamura T, Schmidt EV. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1992;89:373–7.
   Google Scholar
• Bradbury J. A two-pronged approach to the clinical use of HGF. Lancet 1998;351:272.
   PubMedGoogle Scholar